---
document_datetime: 2025-12-02 05:04:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ontilyv.html
document_name: ontilyv.html
version: success
processing_time: 0.1092726
conversion_datetime: 2025-12-24 20:33:57.360312
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ontilyv

[RSS](/en/individual-human-medicine.xml/67523)

##### Lapsed

This medicine's authorisation has lapsed

opicapone Medicine Human Lapsed

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ontilyv](#news-on)
- [More information on Ontilyv](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 21 February 2025, the marketing authorisation of Ontilyv (opicapone) ceased to be valid in the European Union (EU).

The cessation of validity is due to the fact that the marketing authorisation holder, Bial Portela &amp; Ca. S.A., had not marketed Ontilyv in the EU since its initial marketing authorisation. In accordance with provisions of the sunset clause 1 , the marketing authorisation of a medicinal product lapsed if the product had not been marketed in any EU Member State within three years of its initial authorisation.

Bial Portela &amp; Ca. S.A. confirmed that the product had not been marketed due to commercial reasons.

Ontilyv was granted marketing authorisation in the EU on 21 February 2022 for use as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors in adults with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

The marketing authorisation was initially valid for a 5-year period.

Ontilyv was a duplicate application to Ongentys, which is marketed throughout the European Union. The marketing authorisation holder will maintain the marketing authorisation for Ongentys.

The European public assessment report for Ontilyv has been updated to reflect that the marketing authorisation is no longer valid.

1 Article 14(5) of Regulation (EC) No 726/2004 (\"sunset clause\")

Ontilyv : EPAR - Medicine Overview

Reference Number: EMA/784718/2021

English (EN) (272.29 KB - PDF)

**First published:** 07/03/2022

**Last updated:** 28/03/2025

[View](/en/documents/overview/ontilyv-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-559)

български (BG) (529.31 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/bg/documents/overview/ontilyv-epar-medicine-overview_bg.pdf)

español (ES) (448.74 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/es/documents/overview/ontilyv-epar-medicine-overview_es.pdf)

čeština (CS) (499.1 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/cs/documents/overview/ontilyv-epar-medicine-overview_cs.pdf)

dansk (DA) (435.96 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/da/documents/overview/ontilyv-epar-medicine-overview_da.pdf)

Deutsch (DE) (454.41 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/de/documents/overview/ontilyv-epar-medicine-overview_de.pdf)

eesti keel (ET) (429.46 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/et/documents/overview/ontilyv-epar-medicine-overview_et.pdf)

ελληνικά (EL) (527.92 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/el/documents/overview/ontilyv-epar-medicine-overview_el.pdf)

français (FR) (450.14 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/fr/documents/overview/ontilyv-epar-medicine-overview_fr.pdf)

hrvatski (HR) (477.93 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/hr/documents/overview/ontilyv-epar-medicine-overview_hr.pdf)

italiano (IT) (445.76 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/it/documents/overview/ontilyv-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (501.84 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/lv/documents/overview/ontilyv-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (491.74 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/lt/documents/overview/ontilyv-epar-medicine-overview_lt.pdf)

magyar (HU) (482.33 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/hu/documents/overview/ontilyv-epar-medicine-overview_hu.pdf)

Malti (MT) (504.61 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/mt/documents/overview/ontilyv-epar-medicine-overview_mt.pdf)

Nederlands (NL) (452.57 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/nl/documents/overview/ontilyv-epar-medicine-overview_nl.pdf)

polski (PL) (491.95 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/pl/documents/overview/ontilyv-epar-medicine-overview_pl.pdf)

português (PT) (441.88 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/pt/documents/overview/ontilyv-epar-medicine-overview_pt.pdf)

română (RO) (506.61 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/ro/documents/overview/ontilyv-epar-medicine-overview_ro.pdf)

slovenčina (SK) (496.41 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/sk/documents/overview/ontilyv-epar-medicine-overview_sk.pdf)

slovenščina (SL) (474.42 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/sl/documents/overview/ontilyv-epar-medicine-overview_sl.pdf)

Suomi (FI) (440.16 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/fi/documents/overview/ontilyv-epar-medicine-overview_fi.pdf)

svenska (SV) (434.63 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/sv/documents/overview/ontilyv-epar-medicine-overview_sv.pdf)

Ontilyv : EPAR - Risk management plan summary

English (EN) (220.97 KB - PDF)

**First published:** 07/03/2022

**Last updated:** 28/03/2025

[View](/en/documents/rmp-summary/ontilyv-epar-risk-management-plan-summary_en.pdf)

## Product information

Ontilyv : EPAR - Product Information

English (EN) (1.42 MB - PDF)

**First published:** 07/03/2022

**Last updated:** 28/03/2025

[View](/en/documents/product-information/ontilyv-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-752)

български (BG) (1.96 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/bg/documents/product-information/ontilyv-epar-product-information_bg.pdf)

español (ES) (1.51 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/es/documents/product-information/ontilyv-epar-product-information_es.pdf)

čeština (CS) (1.63 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/cs/documents/product-information/ontilyv-epar-product-information_cs.pdf)

dansk (DA) (1.5 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/da/documents/product-information/ontilyv-epar-product-information_da.pdf)

Deutsch (DE) (1.62 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/de/documents/product-information/ontilyv-epar-product-information_de.pdf)

eesti keel (ET) (1.37 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/et/documents/product-information/ontilyv-epar-product-information_et.pdf)

ελληνικά (EL) (2.06 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/el/documents/product-information/ontilyv-epar-product-information_el.pdf)

français (FR) (1.49 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/fr/documents/product-information/ontilyv-epar-product-information_fr.pdf)

hrvatski (HR) (1.66 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/hr/documents/product-information/ontilyv-epar-product-information_hr.pdf)

íslenska (IS) (1.31 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/is/documents/product-information/ontilyv-epar-product-information_is.pdf)

italiano (IT) (1.53 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/it/documents/product-information/ontilyv-epar-product-information_it.pdf)

latviešu valoda (LV) (1.81 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/lv/documents/product-information/ontilyv-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.71 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/lt/documents/product-information/ontilyv-epar-product-information_lt.pdf)

magyar (HU) (1.56 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/hu/documents/product-information/ontilyv-epar-product-information_hu.pdf)

Malti (MT) (1.83 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/mt/documents/product-information/ontilyv-epar-product-information_mt.pdf)

Nederlands (NL) (1.49 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/nl/documents/product-information/ontilyv-epar-product-information_nl.pdf)

norsk (NO) (1.46 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/no/documents/product-information/ontilyv-epar-product-information_no.pdf)

polski (PL) (1.85 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/pl/documents/product-information/ontilyv-epar-product-information_pl.pdf)

português (PT) (1.53 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/pt/documents/product-information/ontilyv-epar-product-information_pt.pdf)

română (RO) (1.78 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/ro/documents/product-information/ontilyv-epar-product-information_ro.pdf)

slovenčina (SK) (1.61 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/sk/documents/product-information/ontilyv-epar-product-information_sk.pdf)

slovenščina (SL) (1.54 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/sl/documents/product-information/ontilyv-epar-product-information_sl.pdf)

Suomi (FI) (1.46 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/fi/documents/product-information/ontilyv-epar-product-information_fi.pdf)

svenska (SV) (1.43 MB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/sv/documents/product-information/ontilyv-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS2702 11/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ontilyv : EPAR - All authorised presentations

English (EN) (105.49 KB - PDF)

**First published:** 07/03/2022

**Last updated:** 28/03/2025

[View](/en/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-301)

български (BG) (122.17 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/bg/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_bg.pdf)

español (ES) (95.22 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/es/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_es.pdf)

čeština (CS) (116.71 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/cs/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (95.84 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/da/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (98.78 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/de/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (94.84 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/et/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (119.56 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/el/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_el.pdf)

français (FR) (92.7 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/fr/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (144.58 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/hr/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (87.87 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/is/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_is.pdf)

italiano (IT) (91.91 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/it/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (111.5 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/lv/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (126.17 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/lt/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (103.28 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/hu/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (120.34 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/mt/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (104.71 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/nl/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (100.15 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/no/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_no.pdf)

polski (PL) (114.34 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/pl/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_pl.pdf)

português (PT) (93.6 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/pt/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_pt.pdf)

română (RO) (111.03 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/ro/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (112.79 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/sk/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (112.48 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/sl/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (96.32 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/fi/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (103.02 KB - PDF)

**First published:**

07/03/2022

**Last updated:**

28/03/2025

[View](/sv/documents/all-authorised-presentations/ontilyv-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ontilyv Active substance opicapone International non-proprietary name (INN) or common name opicapone Therapeutic area (MeSH) Parkinson Disease Anatomical therapeutic chemical (ATC) code

- N04
- N04BX04

### Pharmacotherapeutic group

Anti-Parkinson drugs

### Therapeutic indication

Ontilyv is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

## Authorisation details

EMA product number EMEA/H/C/005782 Marketing authorisation holder

Bial Portela &amp; Companhia S.A.

Apartado 19 A

Opinion adopted 16/12/2021 Marketing authorisation issued 21/02/2022 Lapse of marketing authorisation 21/02/2025 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ontilyv : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (469.32 KB - PDF)

**First published:** 25/08/2022

**Last updated:** 28/03/2025

[View](/en/documents/procedural-steps-after/ontilyv-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Ontilyv : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/129900/2022

English (EN) (639.13 KB - PDF)

**First published:** 07/03/2022

**Last updated:** 28/03/2025

[View](/en/documents/assessment-report/ontilyv-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Ontilyv

Adopted

Reference Number: EMA/CHMP/679312/2021

English (EN) (133.91 KB - PDF)

**First published:** 17/12/2021

**Last updated:** 28/03/2025

[View](/en/documents/smop-initial/chmp-summary-opinion-ontilyv_en.pdf)

#### News on Ontilyv

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024) 22/03/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021) 17/12/2021

#### More information on Ontilyv

- [Ontilyv - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/ontilyv)
- [EMEA-003406-PIP01-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-003406-pip01-23)

**This page was last updated on** 28/03/2025

## Share this page

[Back to top](#main-content)